Clinical Effect of Granulocyte Colony-stimulating Factor on Neutrophils and Leukemic Cells in Myelogenous Leukemia: Analysis
| Autor: | Nobuhiko Tominaga, Hirotoshi Shibata, Fumimaro Takaku, Tatsuro Matsunashi, Masafumi Yoshimura, Akira Hiraoka, Jun Ishikawa, Hiroyuki Nakamura, Tohru Masaoka, Hirofumi Teshima |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Myeloid Adolescent Neutrophils medicine.medical_treatment Recombinant Granulocyte Colony-Stimulating Factor Gastroenterology Leukocyte Count Myelogenous Leukemia Myelogenous Chronic BCR-ABL Positive hemic and lymphatic diseases Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Radiology Nuclear Medicine and imaging Chemotherapy business.industry Remission Induction fungi Induction chemotherapy General Medicine Middle Aged medicine.disease Chemotherapy regimen Recombinant Proteins Granulocyte colony-stimulating factor Leukemia Myeloid Acute Leukemia medicine.anatomical_structure Oncology Immunology Female business |
| Zdroj: | Japanese Journal of Clinical Oncology. |
| ISSN: | 1465-3621 |
| Popis: | Clinical experiences with recombinant granulocyte colony-stimulating factor (rhG-CSF) in 13 acute (AML) and four chronic (CML) myelogenous leukemia patients are reported. Sixteen patients received rhG-CSF in support of treatment for life threatening infections and one CML patient in support of induction chemotherapy. After their first induction chemotherapy, six out of eight AML patients showed a rapid increase of neutrophils, recovered from infections and achieved complete remission (CR). One patient, in whom both neutrophils and blasts had increased during rhG-CSF administration, achieved CR through the next administration of chemotherapy (CR rate 87.5%). The last of the eight AML patients showed no increase of neutrophils, and died of interstitial pneumonitis. Two of five AML patients who received rhG-CSF after reinduction chemotherapy for relapsed or refractory leukemia achieved CR, a rate of 40%. In one of the two, the administration of rhG-CSF prior to induction chemotherapy seemed advantageous in achieving CR. During rhG-CSF administration, an increase of blastic cells in peripheral blood was observed in four out of all 13 AML patients. One of three CML patients, with a lymphoid crisis, showed an increase only of neutrophils, and recovered from infection. The other two showed increases of both neutrophils and blasts. One patient with CML in blastic crisis, undergoing induction chemotherapy with rhG-CSF administration, returned to the chronic phase. These clinical experiences suggest rhG-CSF to be effective in supporting infection therapy and in possibly enhancing the sensitivity of myelogenous leukemic blasts to antileukemic agents. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|